[Form 4] Cytokinetics Inc. Insider Trading Activity

Rhea-AI Filing Summary

Dr. Edward M. Kaye, a director of Cytokinetics Inc. (CYTK), reported a sale of 6,756 shares of the issuer's common stock on 09/02/2025 at a reported price of $50 per share, leaving him with 23,230 shares beneficially owned following the transaction. The Form 4 was filed by one reporting person and signed by an attorney-in-fact.

Positive

• None.

Negative

• Director sale reported: 6,756 shares sold at $50 on 09/02/2025, reducing holdings to 23,230 shares
• Limited disclosure on intent: Form indicates a 10b5-1 plan checkbox but provides no details about plan terms or motivation

Insights

Financial Analyst

TL;DR Insider director sold 6,756 shares at $50, retaining 23,230 shares—transaction is a routine disclosure without performance context.

This Form 4 documents a director sale rather than an acquisition. The sale size and remaining holding are explicitly stated, but the filing includes no information about motivation, 10b5-1 plan specifics beyond indicating a plan checkbox, or company performance metrics. Without context on prior holdings, historical sales, or trading plan terms, it's not possible to assess whether this alters valuation or signals material change.

Corporate Governance Expert

TL;DR A director-initiated sale was reported; governance disclosure requirements were met but intent is not provided.

The filing shows the reporting person is a director and that the transaction was reported on Form 4 with an attorney-in-fact signature. The form indicates the Rule 10b5-1(c) plan box was checked, suggesting the sale may have been pursuant to a written trading plan, although the filing does not include plan details. From a governance perspective, the disclosure is compliant; however, absence of plan detail limits ability to evaluate whether trading was pre-planned or opportunistic.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kaye Edward M. MD

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2025		S		6,756	D	$50	23,230	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ John Faurescu, attorney-in-fact for Dr. Kaye	09/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did CYTK director Edward M. Kaye report on Form 4?

He reported a sale of 6,756 shares of Cytokinetics common stock on 09/02/2025 at $50 per share, leaving 23,230 shares owned.

Was the sale reported as part of a 10b5-1 trading plan?

The form has the 10b5-1 plan checkbox checked, indicating the transaction was intended to satisfy Rule 10b5-1(c) affirmative defense, but no plan details are provided.

Who signed the Form 4 for Dr. Kaye?

The Form 4 was signed by John Faurescu, attorney-in-fact, on 09/02/2025.

How many shares does Dr. Kaye beneficially own after the transaction?

The filing reports 23,230 shares beneficially owned following the reported sale.